Maureen M Jonas, Rene Romero, Philip Rosenthal, Chuan-Hao Lin, Gabriella Verucchi, Jessica Wen, William F Balistreri, Suzanne Whitworth, Sanjay Bansal, Daniel H Leung, Michael R Narkewicz, Regino P Gonzalez-Peralta, Alessandra Mangia, Wikrom Karnsakul, Girish S Rao, Jiang Shao, Jan de Jong, Bandita Parhy, Anu Osinusi, Kathryn Kersey, Karen F Murray, Etienne M Sokal, Kathleen B Schwarz
BACKGROUND: The safety and efficacy of sofosbuvir-velpatasvir in children aged 3-17 years with chronic hepatitis C virus (HCV) infection of any genotype were evaluated. METHODS: In this Phase 2, multicenter, open-label study, patients received once daily for 12 weeks either sofosbuvir-velpatasvir 400/100 mg tablet (12-17 years), 200/50 mg low dose tablet or oral granules (3-11 years and ≥17 kg), or 150/37.5 mg oral granules (3-5 years and <17 kg)...
April 21, 2024: Journal of Pediatric Gastroenterology and Nutrition